A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

NCT03818607 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: ABP 959
DRUG: Eculizumab

Sponsor

Amgen